Schwannomas are peripheral nerve sheath tumors that often occur in the setting of an inherited tumor predisposition syndrome, including neurofibromatosis types 1 (NF1) and 2 (NF2), familial schwannomatosis and Carney complex. Loss of the NF2 tumor suppressor (encoding NF2, or Merlin) is associated with upregulation of the Rac1 small GTPase, which is thought to have a key role in mediating tumor formation. In prior studies, we generated a mouse model of schwannomas by performing tissue-specific knockout (KO) of the Carney complex gene Prkar1a, which encodes the type 1A regulatory subunit of protein kinase A. These tumors exhibited down-regulation of Nf2 protein and an increase in activated Rac1. To assess the requirement for Rac1 in schwannoma formation, we generated a double KO (DKO) of Prkar1a and Rac1 in Schwann cells and monitored tumor formation. Loss of Rac1 reduced tumor formation by reducing proliferation and enhancing apoptosis. Surprisingly, the reduction of tumor formation was accompanied by re-expression of the Nf2 protein. Furthermore, activated Rac1 was able to downregulate Nf2 in vitro in a Pak-dependent manner. These in vivo data indicate that activation of Rac1 is responsible for suppression of Nf2 protein production; deficiency of Nf2 in Schwann cells leads to loss of cellular growth control and tumor formation. Further, PKA activation through mutation in Prkar1a is sufficient to initiate Rac1 signaling, with subsequent reduction of Nf2 and schwannomagenesis. Although in vitro evidence has shown that loss of Nf2 activates Rac1, our data indicate that signaling between Nf2 and Rac1 occurs in a bidirectional fashion, and these interactions are modulated by PKA.
INTRODUCTION
Schwannomas are benign tumors of the peripheral nervous system that have been well studied because of their association with neurofibromatosis syndromes. Neurofibromatosis type 1 (NF1, Online Mendelian Inheritance in Man (OMIM) #162200) and neurofibromatosis type 2 (NF2) ([OMIM #101000) syndromes are caused by inactivating mutations in the RasGAP neurofibromin 1 (encoded by the NF1 gene) and ezrin-radixin-moesin family protein neurofibromin 2 (Merlin or Schwannomin, encoded by NF2), respectively. 1 In addition to these syndromes, schwannomas are also observed in two other autosomal dominant tumor syndromes. Familial schwannomatosis (OMIM #162091) is caused by mutations in the SWI/SNF complex protein SMARCB1 and is rarely associated with non-neural tumors. 2 Lastly, pigmented schwannomas are seen in patients with Carney complex, a tumor predisposition bearing significant similarities to multiple endocrine neoplasia syndromes. Carney complex is characterized by tumors of various endocrine glands, bone and cartilage tumors, Schwann cell tumors and skin discoloration. This condition is caused by lossof-function mutations in PRKAR1A, the gene which encodes type 1A regulatory subunit of cyclic AMP (cAMP)-dependent protein kinase, PKA. Loss of PRKAR1A causes dysregulation of PKA activity, with elevated basal and stimulated PKA activity. 3, 4 cAMP regulates a number of key cellular processes such as cell growth, differentiation, gene transcription and ion channel conductivity. In Schwann cells, activation of the cAMP/PKA pathway promotes cell growth, cell cycle progression 5 and required for myelin formation. 6 PKA phosphorylates a wide variety of physiological substrates, including, neurofibromin1 7 and 2 (Merlin). 8 PKA is able to phosphorylate Merlin at Serine-518, at Serine-10 where phosphorylation of these residues appears to alter Merlin's interaction with actin cytoskeleton to cause morphologic and mobility alterations. 9 Notably, the Ser-518 site is also targeted by p21-activated kinases (PAKs). 10 Phosphorylation of Nf2 has been demonstrated for PAKs 1,2 and 6, although others have not been tested. 11 One report has suggested that PAKs are primarily activated by Cdc42 in Schwann cells, 12 although this question has not been studied extensively. Functionally, mutation in Nf1 leads to increased intracellular cAMP in Schwann cells 13 and increased PKA activity, which would mimic the increased PKA activity caused by loss of Prkar1a.
aberrant differentiation of the cranial neural crest. 16 Prkar1a-null schwannomas demonstrated post-transcriptional loss of Nf2 protein. Analysis of signaling pathways thought to lie downstream from Nf2 showed no activation of Akt, Erk or an increase in GTP-loaded Ras. However, study of other small G-proteins demonstrated significant enhancement of activated Rac1. Inhibition of Rac-Pak activity in confluent cells has been proposed to be one of the key means by which NF2 inhibits proliferation of confluent cells. 17 Thus, based on these data, we proposed that activation of PKA in Schwann cells (caused by loss of Prkar1a) led to reduction in Merlin, and thence to an increase in Rac1 activity as the key pathway in tumorigenesis.
In the present study, we sought to test the hypothesis that Rac1 is a downstream effector that is essential and is required for Schwann cell tumorigenesis in T3;R1a KO model. To pursue this question in vivo, we introduced a conditional null allele of Rac1 into these mice and monitored tumor formation. We report that Rac1 KO in this setting significantly reduces tumorigenesis. Surprisingly, ablation of Rac1 led to re-expression of Nf2, suggesting that there is bidirectional signaling between Nf2 and Rac1, and these interactions are modulated by PKA. These observations have important implications for understanding both Schwann cell development and Schwann cell tumorigenesis.
RESULTS

Deletion of Rac1 reduces schwannoma formation in the Prkar1a
KO model T3;R1a KO ;Rac1 WT mice have been previously generated in our laboratory. 15 Because the TEC3 driver expresses cre in a limited subset of facial neural crest derivatives, 14 it is highly suitable for studying Schwann cell tumorigenesis. 15 Tumors derived from T3;R1a KO ;Rac1 WT mice showed upregulated Rac1 activity. To assess the requirement of Rac1 in tumorigenic process, we used TEC3 cre line to generate mice lacking both Prkar1a and Rac1 in a subset of facial Schwann cell.
T3;R1a KO ;Rac1 KO (DKO) and T3;R1a KO ;Rac1 Het (heterozygous (Het)) mice were generated by crossing T3;R1a KO ;Rac1 WT mice with mice carrying a conditional null allele of Rac1. All genotypes of mice were born at expected Mendelian frequencies (data not shown) and allowed to age to 40 weeks, a time by which 480% of T3;R1a KO mice developed Schwann cell tumors on the face. 15 Although heterozygosity for Rac1 did not affect tumor incidence (Figure 1) . Also, the incidence of bilateral tumors observed in Prkar1a/Rac1 DKO mice (6%) was much lower than that observed in Het (43.6%) or wild-type (WT) (41%) mice for Rac1. We have previously described that tumors in T3;R1a KO ;Rac1 WT can grow up to nearly 1.5 cm in diameter with no signs of metastases. 15 As shown in Figures 1a-f . No metastatic disease was observed in any of the schwannoma models studied.
To confirm that deletion of Rac1 allele in limited subset of facial neural crest cells does not affect normal development, we also generated Tec3;Rac1 loxP/loxP (T3;Rac1 KO ) mice. These mice carried the ROSA26 lacZ reporter allele in order to confirm cre expression by LacZ staining 18 (Supplementary Figure 1) . Histological analysis did not show any aberration or alteration in neural crest development (data not shown). A cohort of mice was allowed to grow until 12 months of age. These mice were completely normal for 1 year and did not show any phenotypic abnormality.
Tumor histology Based on guidelines for classification of genetically engineered mouse Schwann cell tumors, 19 T3;R1a KO ;Rac1 WT tumors were categorized previously as schwannomas given their characteristics on S-100 immunohistochemistry. 20 According to this classification scheme, tumors with mesenchymal, epithelial or neuroendocrine differentiation are grade III peripheral nerve sheath tumors with divergent differentiation. To assess histologic changes induced by loss of Rac1, we studied a subset of tumors from each genotype at the histopathologic level ( WT was noted and found to be significant (P ¼ 0.002).
To verify these findings, a similar analysis was performed using TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) as an additional marker for apoptosis (Supplementary Figure 2) . There was an obvious difference between T3;R1a KO ; Rac1 KO . In contrast to the proliferation/apoptosis data, levels of GTP-Rac1 did not appear significantly different between tumors Het or WT.
In these blots, we noticed that levels of total Rac1 in whole tumor lysates remained detectable despite the almost complete loss of GTP-bound Rac1 (Figure 3a , middle). To determine whether this represented cross reactivity with other Rac isoforms or represented a contribution from stromal cells within the tumor, we analyzed Rac by immunohistochemistry using the same antibody ( Figure 3b ). This analysis demonstrated that tumors carrying one or two WT alleles for Rac1 exhibited both nuclear and cytoplasmic staining; however, tumors with KO of Rac1 exhibited primarily cytoplasmic staining. We interpret this finding as indicating that Rac identified by western blot and IHC represent other Rac isoforms. The GTP pull-down assay demonstrates that Rac1 was not activated in DKO tumors.
Effect of Rac1 ablation on NF2
Loss of NF2 is a common event in human schwannomas, even those without a germline mutation in the gene. 21 Consistent with this observation in human patients, our prior work demonstrated that ablation of Prkar1a in T3;R1a KO ;Rac1 WT -associated schwannomas exhibited a post-transcriptional reduction of Nf2. 15 As Rac1 is a major downstream target of NF2, 22 we wanted to determine whether ablation of Rac1 had any effects on Nf2 levels. As an initial study, we performed immunofluorescence on frozen sections of tumors from T3;R1a KO (Figure 4a , left).
15 Surprisingly, ablation of Rac1 led to restoration of Nf2 immunostaining in the tumor (Figure 4a, right) , whereas tumors heterozygous for Rac1 had a lower but detectable level of immunostained Nf2 (Figure 4a, center) . Positive staining in the surrounding tumor capsule served as an internal control for Nf2 reactivity in each sample (Figure 4a, insets) . In order to verify that these changes were not artifacts of immunofluorescence, we isolated the central region of tumor tissue from all three groups of mice and prepared proteins for western blotting, using primary rat Schwann cells as a reference. As observed in the immunofluorescence assay, T3;R1a KO ;Rac WT had a minimal amount of Nf2 protein, which increased with genetic reduction in Rac1 (Figure 4b ). To assess whether phosphorylation of Nf2 was altered in response to these manipulations, we also used an antibody that specifically detects phospho-Ser518 in Nf2. Although increased pS518-Nf2 was detected in the T3;R1a KO ;Rac1 KO lysates, it paralleled increases in total Nf2, such that the ratio of phosphorylated to total Nf2 was not altered (Supplementary Figure 3) .
Our previous study demonstrated that Nf2 protein reduction in T3;R1a KO ;Rac1 WT tumors was accompanied by increases in Nf2 messenger RNA (mRNA). Analysis of Rac1 KO tumors by quantitative real-time-PCR demonstrated that levels of mRNA varied inversely with Nf2 protein levels ( Figure 4c ). As previously observed, T3;R1a KO ;Rac1 WT tumors had the least Nf2 protein but highest mRNA levels, whereas T3;R1a KO ;Rac1 KO had highest protein levels with the lowest mRNA levels. Consistent with our prior data, 15 T3;R1a KO ;Rac1 WT tumors had about three-fold elevation of Nf2 mRNA compared with normal mouse sciatic nerve, whereas T3;R1a KO ;Rac1 KO tumors had a 1.7-fold elevation.
Rac1 downregulates Nf2 via Pak2
In order to corroborate the hypothesis that activated PKA caused downregulation of the Nf2 protein through the activation of Rac1, we introduced activated Rac1 into normal rat Schwann cells and studied the effect on Nf2 protein abundance. As observed, introduction of activated Rac1 (Rac1 L61 ) led to a substantial decrease in Nf2 protein level (Figure 5a and Supplementary Figure 4 ) compared with Rac1 WT . Activation of Rac1 in Schwann cells has been proposed to affect Nf2 independently of Nf1. 17 In agreement with this concept, introduction of Rac1 L61 into rat Schwann cells had no effect on Nf1 levels (Supplementary Figure 5A) . Similarly, although there was some variability in Nf2 expression among mouse tumors, there was no significant correlation between Nf1 levels and genotype (Supplementary Figure 5B) .
Lastly, Rac1 is reported to signal through class I Paks, and this signaling is inhibited by the Pak1 autoinhibitory domain (PID). showed an increase in mRNA, although levels were still relatively low. Increase in Pak6 protein in the tumors appeared to be much larger than the change in mRNA level.
As PAK protein levels may not correlate with activation status, we performed immunoprecipitate(IP)-kinase assays for Pak isoforms using lysates from rSCs and six T3;R1a KO tumors (Figure 5d ). In this analysis, we observed a significant elevation of the activity of Pak2. Although there were small changes in the activity of other Paks, none were significantly different compared with rSCs. We did not evaluate Pak3 and Pak5 because no expression was seen at either protein or mRNA level.
Lastly, to correlate ablation of Rac1 with changes in Pak activity, we compared the expression of Paks among T3;R1a KO Het tumors exhibited higher activity. These data indicate that the Rac1 effect occurs through Pak signaling, specifically Pak2, in these tumors.
DISCUSSION
Loss of PRKAR1A/Prkar1a tumor suppressor is tumorigenic in cAMP-responsive tissues, including Schwann cells, in both humans and mice. 4, 20 In this manuscript, we report the results of our investigation to determine whether Rac1 is required for Prkar1a-associated Schwann cell tumorigenesis. Rac1 is known to have an important role in normal Schwann cell function, including the regulation of cell shape, polarity, migration, cytokinesis, gene transcription, apoptosis, cell cycle progression, cell adhesion promoting dynamic actin remodeling, lamellipodia formation and random cell migration. [24] [25] [26] [27] [28] It is also responsible for the formation of myelin sheaths in central nervous system. 29 Previous studies have shown that conditional ablation of Rac1 in the Schwann cell lineage affects radial sorting of axons and leads to a failure to form lamellipodia, necessary for proper Schwann cell process extension and stabilization. [30] [31] [32] [33] Interestingly, unlike the related small G-protein Rho, 34 Rac1 lacks PKA phosphorylation sites. Although it has been suggested that integrin signaling may mediate PKARac crosstalk, 35 there is no known mechanism by which activation of PKA directly enhances Rac1 activity.
On the basis of this fact and prior reports that Nf2 serves as a negative regulator of Rac1 function, 22, 36, 37 we hypothesized that ablation of Rac1 from Prkar1a KO Schwann cell tumors would reduce tumor formation by reducing a key signaling mechanism downstream from Nf2.
Initial studies linking Rac1 and Nf2 showed that cells lacking Nf2 have increased levels of activated Rac1, as judged primarily by increases in downstream targets. 22 The same phenomenon was observed in lysates from human schwannomas. 38 Prior data has suggested that either Rac-activated Pak or cAMP-activated PKA can phosphorylate Nf2 on Ser518 and that this modification abrogates Nf2's normal growth suppressive ability. 8, 39 Although ablation of Rac1 did, in fact, reduce tumor formation, our data suggest that the interplay between PKA, Rac1 and Nf2 in vivo appears to be more complex. Schwann cell tumors with activated PKA (caused by ablation of Prkar1a) do not exhibit hyperphosphorylated Nf2; rather, Nf2 protein is lost from tumors. When Rac1 was knocked out of these tumors, Nf2 was restored in the tumors that developed, suggesting that PKA's effects are indirect and are mediated through Rac1 activation. Thus, Rac1's ability to promote Schwann cell tumors may rely on its ability to suppress Nf2 protein abundance, rather than altering Nf2 function. This effect does not appear to be mediated by alterations in Nf2 phosphorylation. When re-expression of Nf2 in the double KO tumors occurs, it causes decreased proliferation and enhanced apoptosis, consistent with previous reports where both decreased proliferation 40, 41 and increased apoptosis 42, 43 were observed in Schwann cells transduced with Nf2. The mechanism by which activation of Rac1 leads to downregulation of Nf2 at the protein level remains obscure. Proteasomal degradation of mutant Nf2 isoforms has previously been demonstrated. 44 Efforts to demonstrate enhanced proteasomal degradation of Nf2 in Prkar1a-null Schwann cells have not recapitulated this observation (GNJ and LSK, unpublished observations). However, these studies may have been limited by the choice of cell line, as Rac1 L61 induced Nf2 degradation, but only in primary cells. Alternatively, degradation of Nf2 may occur via other means yet to be identified. Other possibilities exist, including induction of microRNAs targeted to Nf2 45 or the direct inhibition of translation of the mRNA. Efforts to define this mechanism are currently underway. Our observations regarding Paks also merit mention. Regardless of mechanism, our data strongly indicate that Pak2 is the Pak isoform downstream from Rac1, which mediates Rac1's ability to downregulate Nf2. This effect is specific for Nf2, as Nf1 is not affected by modulation of Rac1-Pak signaling. More intriguing is the relative lack of correspondence between Pak isoform mRNA, protein and activity levels ( Figure 5 ). These studies highlight the need to specifically investigate these kinases at functional level, and not solely through mRNA or protein abundance. It is possible that the same intracellular pathways causing dissociation between Nf2 mRNA and protein levels (Figure 4 ) have this same effect on Paks, especially Paks 4 and 6. Despite high levels of Pak6 in tumors, we do not observe activation of this kinase, and its function in schwannomas remains obscure. Recent data suggest that Pak6 can phosphorylate and inactivate the proapoptotic protein, Bad, in prostate cancer cells. 46 However, this mechanism may not be applicable to schwannomas, which show increased levels of apoptosis in DKO tumors despite high levels of Pak6.
In conclusion, KO of PRKAR1A/Prkar1a in the Schwann cell lineage leads to loss of Nf2 at protein level and that this loss appears to be mediated by activation of Rac1 in this tissue. Our data indicate that the Rac1 effect is mediated by Type I Paks specifically Pak2. These data should lead to an enhanced understanding of the regulation of Nf2 in vivo, and suggests that inhibition of Rac1 or Pak2 may be a viable therapy for treating Schwann cell tumors.
MATERIALS AND METHODS
Mouse experiments
All genetically modified animals were maintained in a sterile environment with 12- KO (n ¼ 52) animals were monitored weekly for tumor onset, which was defined as the age at which a tumor of 0.5-cm linear dimension (as measured by calipers) was first detected. Mice with bilateral tumors were designated as having tumor onset at time the first tumor reached 0.5 cm.
Rac1 activation assays
Active Rac1 was affinity precipitated using PAK1-PBD, separated by SDS-PAGE, and immunoblotted with anti-Rac1 antibody according to manufacturer's instructions (Millipore, Billerica, MA, USA, cat #17-441). Activity assays were performed on five tumors of each genotype. Total Rac1 was measured from corresponding whole tumor lysates normalized to b-Actin (Sigma-Aldrich, St Louis, MO, USA) as loading control. Quantitation of blots was determined using Genetools imaging software (Spectronics Corporation, Westbury, NY, USA).
Western blot
Proteins from tumors were homogenized and lysed under non-denaturing conditions (Cell lysis buffer, Cell Signaling, Danvers, MA, USA). Samples were separated on NuPAGE 4-12% Bis-Tris gels (Invitrogen, Carlsbad, CA, USA), transferred to nitrocellulose, and probed with the following antibodies: PAK1 (#2602), PAK2 (#2608), PAK3 (#2609) and PAK4 (#3242) (CST, Danvers, MA, USA); NF1 (sc-67), NF2 (sc-331), PAK5 (sc-22156), PAK6 (H-300) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and b-Actin (Sigma-Aldrich).
Histology
In order to visualize cre activity using LacZ staining, mice were bred to carry the ROSA26 lacZ allele. 48 Pups at postnatal day 2 (P2) were sacrificed and heads washed in cold phosphate-buffered saline. Whole-mount X-gal staining was performed as described. 49 Heads were visualized under dissecting microscope and images taken using Zeiss digital camera with Axio Vision 4.3 software (Carl Zeiss GmbH, Jena, Germany). Specimens were dehydrated and embedded in paraffin. Sections were cut through trigeminal ganglion and visualized and images captured under a microscope (Olympus BX50, Center Valley, PA, USA) with Spot Basic v4.1 software (Spot Imaging Solutions, Sterling Heights, MI, USA).
Hematoxylin and Eosin (H/E) staining was performed using Leica autostainer (Leica Microsystems Inc., Bannockburn, IL, USA). Alcian blue staining was performed manually in 1% Alcian blue (Sigma-Aldrich) prepared in 0.1 N HCl for 30 min. Nuclei were counterstained using Nuclear Fast Red (Sigma-Aldrich) for 5 min, then sections were dehydrated and cover-slipped.
Immunofluorescence/Immunohistochemistry (IF/IHC)
For IF, freshly dissected tumor tissues were frozen in Tissue Tek Optimal Cutting Temperature Compound (Sakura Finetek USA Inc., Torrence, CA, USA). 5 mm sections were fixed using cold acetone and permeabilized in 0.1% sodium citrate with 0.1% Triton-X100 detergent (Sigma-Aldrich). Primary antibody was prepared in 3% bovine serum albumin in phosphatebuffered saline. Slides were incubated with primary antibodies at 4 1C overnight, washed and incubated with Alexafluor-488 conjugated secondary antibodies (Invitrogen) for 25 min in dark. Samples were then washed, mounted with DAPI mounting medium (Vector Labs, Burlingame, CA, USA), and visualized using Zeiss Axioskop 40 microscope (Carl Zeiss GmbH) and Axiovision software (Carl Zeiss GmbH).
For IHC, samples were fixed overnight in 10% formalin, processed and embedded in paraffin. IHC was developed by adding DAB chromogen reagent (Vector Labs) to each section for 1-2 min before counterstaining with hematoxylin, dehydration and cover-slipping. Following antibodies were used: Cleaved caspase-3 (CST#9661), Ki67 (Clone TEC-3, DAKO, Carpinteria, CA, USA). TUNEL staining was performing using a commercial kit per the manufacturer's instructions (#L00297, GenScript, Piscataway, NJ, USA). For Rac1 IHC, we used the same antibodies as for Rac1 pull down. Samples were analyzed on an Olympus BX50 microscope, and images captured using Spot Basic v4.1 software.
Quantitative real-time-PCR RNA was isolated from mouse tumors and converted to cDNA with BioRad iScript cDNA Synthesis Kit (BioRad Laboratories, Hercules, CA, USA). cDNA was subject to quantitative real-time-PCR using iQ SYBR Green Supermix Kit (BioRad) as per manufacturer's instructions. Expression data were pooled for all experiments to derive the data presented. Reactions were each performed in triplicate. Primers are previously described. 15 Cell culture and transfection Primary rSCs were isolated from neonatal rat pups using standard methods.
50 pRK5-myc-Rac1-wt and pRK5-myc-Rac1-Q61L (constitutively active) plasmids were generated in lab of Dr Gary Bokoch and obtained from Addgene (Cambridge, MA, USA; plasmids 12985 and 12983, respectively). The PID construct has been described 23 and was gracious gift of Dr Jonathan Chernoff. Cells transfections were performed with Amaxa Nucleofector using reagents from manufacturer (Rat Neural Stem Cell Nucleofector Kit from Lonza, Allendale, NJ, USA).
PAK IP-kinase assay
Two hundred micrograms of protein was used as starting material to IP each Pak isoform for subsequent kinase activity assays. For our initial studies, we used lysates from rSCs and six TEC3KO tumors for analysis. For comparison among tumors from T3;R1a KO ;Rac WT , T3;R1a KO ;Rac Het and T3;R1a KO ;Rac KO mice, three independent tumors were analyzed. In brief, samples were pre-cleared with 1.0 mg rabbit IgG prior to IP, and the antibodies used for PAK were same as those used for western blots. Protein A/G beads (Santa Cruz Biotechnology) were used to pull down the IgG-Pak complexes, which were subsequently resuspended in and equal volume of 0.5 mg/ml myelin basic protein (Sigma-Aldrich). Kinase assays were performed by adding 3 Â hot mix containing 50 mM Hepes (pH 7.5), 10 mM MgCl 2 , 150 mM ATP and 10 mCi per reaction with g-32 P ATP. Samples were incubated at 30 1C for 30 min and then 10 ml of each reaction was spotted on P81 paper (Whatman, Piscataway, NJ, USA). Counts per minute were read on scintillation counter, and samples normalized to background readings from negative controls. Each sample was tested in triplicate for kinase activity to control for variability.
Statistics
Tumor onset was analyzed by generation of Kaplan-Meier curves. On the basis of the tumor-free survival curve shown, we used a double-sided logrank test at a ¼ 0.05 to compare time with tumor onset of the TEC3KO mice (as the 'baseline') with other mice. Unpaired t-tests were used for all other analyses assuming Gaussian populations with a 95% confidence interval. Data are presented as mean ± s.e. Differences were analyzed with Student's t-test, and significance set at Po0.05.
